1. Improving Effective Basal Insulin Use in Clinical Practice

3. ADA Guideline Recommendations for Basal Insulin Use in T2D

4. Barriers to Insulin Use: Clinician-Level Factors

5. Barriers to Insulin Use: System-Level Factors

6. Barriers to Insulin Use: Patient-Level Factors

7. Communication Between Clinicians and Patients

8. Generics vs Biosimilars/Biologics

9. Follow-On Basal Insulin Therapy

10. Comparison of Follow-On Insulin With Traditional Insulin

11. Place of Follow-On Basal Insulin in Clinical Practice

12. Patient Opinion on Use of Biosimilar Insulin

13. Continued Role of NPH Insulin

14. Patient Communication: Switching From U100 Glargine to Follow-On Insulin Glargine U100

15. Experience With Biosimilar Glargine in Europe

16. Role of Basal Insulin in Type 2 Diabetes

17. Follow-On Basal Insulin Glargine in Insulin-Naive Patients

18. Follow-On Basal Insulin: Cost

19. Key Takeaways

20. Abbreviations